% | $
Quotes you view appear here for quick access.

Myrexis, Inc. Message Board

  • eastcoasttroll eastcoasttroll Feb 2, 2010 8:46 AM Flag

    Breaking it down: BioMed Report 1/10


    Read the whole article -- too long to copy to this message board. Here is a clip from this 1/3/2010 article:

    The deal seems very positive for both companies and their shareholders. For Myriad, they have essentially purchased Javelin for an all stock transaction which values JAV at less than $100 million. This allows Myriad to begin reaping the benefits of Dyloject, which is already sold in the EU and which analysts and executives of both companies estimate can reach at least $250 million a year in sales in the United States. Myriad also will now have access to Ereska, a drug which narrowly missed its Phase III trial endpoint in the summer of 2009 and is used as a proprietary nasal formulation of ketamine for treatment of acute moderate-to-severe pain. Ereska is optimized for use as a pain medication and may offer a safe, non-opioid alternative for the treatment of moderate-to-severe pain. Assuming Dyloject is approved and marketed this year, Myriad will use the extensive cash flow that is predicted to come from Dyloject in the United States, to further their own drug studies for their product candidates for cancer and HIV, Azixa and MCP-4326. Myriad has approximately $165 million in cash on hand, and with approximately 25 million shares of Myriad Pharmaceuticals stock outstanding, the shares trade for much less than cash. Bolstering their pipeline and anticipated cash flow with this transaction, could reap huge rewards for Myriad in the near future.>>

    This topic is deleted.